- Home
- TXN vs AZN Comparison
TXN vs AZN Comparison
Compare TXN & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXN | AZN |
|---|---|---|
| Founded | 1930 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.6B | 250.7B |
| IPO Year | 2002 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TXN | AZN |
|---|---|---|
| Price | $281.13 | $163.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 1 |
| Target Price | ★ $265.46 | N/A |
| AVG Volume (30 Days) | ★ 4.8M | 2.7M |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.11% | 1.73% |
| EPS Growth | ★ 4.81 | N/A |
| EPS | ★ 3.82 | N/A |
| Revenue | ★ $17,682,000,000.00 | N/A |
| Revenue This Year | $11.74 | $10.34 |
| Revenue Next Year | $10.43 | $6.43 |
| P/E Ratio | $72.86 | ★ $31.91 |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $152.73 | $80.48 |
| 52 Week High | $334.03 | $212.71 |
Technical Indicators
Market Signals| Indicator | TXN | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 62.28 | 48.25 |
| Support Level | $274.83 | $154.89 |
| Resistance Level | $288.91 | $165.74 |
| Average True Range (ATR) | 7.47 | 2.81 |
| MACD | 2.69 | 0.29 |
| Stochastic Oscillator | 88.83 | 51.65 |
Price Performance
Historical ComparisonAbout TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.